Chinese pharma giants Innovent Biologics and Shenzhen Chipscreen Biosciences join forces for advanced colorectal cancer drug trial
Innovent Biologics and Shenzhen Chipscreen Biosciences have entered into a major collaboration to assess the potential of a combination therapy for advanced colorectal cancer. The combination will include Innovent’s Tyvyt (sintilimab injection), a PD-1 monoclonal antibody, alongside IBI305, a proposed biosimilar to Roche’s bevacizumab. These two drugs will be evaluated alongside Chidamide, an epigenetic modulator […]